Be Well Medical Center | Berkley, MI

Research site

(Unclaimed)

Location

1964 11 Mile Road, Berkley, Michigan, United States of America

Site insights

Top conditions

Top treatments

Emtricitabine

Tenofovir Alafenamide

Lenacapavir

Tenofovir Disoproxil Fumarate

Bictegravir

TDF

TAF

Rilpivirine

Ritonavir

Elvitegravir

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 43 total trials

A Clinical Trial of STP0404 in Adults With HIV-1 Infection

The purpose of this study is to evaluate the antiviral effect, safety, tolerability, and pharmacokinetics of STP0404 in adult participants living wit...

Enrolling

HIV-1-infection

Drug: High-dose STP0404 (Pirmitegravir)

Drug: Low-dose STP0404 (Pirmitegravir)

A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

The goal of this study is to test the effectiveness, safety, and tolerability of the combination of broadly neutralizing antibodies (bNAbs) (teropavi...

Active, not recruiting

HIV Infections

Drug: Lenacapavir Tablet

Drug: Zinlirvimab

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)

The primary objectives of this study are to evaluate the antiretroviral activity of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting

HIV-1 Infection

Drug: BIC/FTC/TAF

Drug: DOR/ISL

Status recently updated

DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Enrolling

Active, not recruiting

HIV-1 Infection

Drug: BIC/FTC/TAF

Drug: Placebo to DOR/ISL

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologicall...

Active, not recruiting

HIV-1 Infection

Drug: B/F/TAF

Drug: LEN

Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (PURPOSE 2)

The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.

Active, not recruiting

Pre-Exposure Prophylaxis of HIV Infection

Drug: PTM F/TDF

Drug: Placebo SC LEN

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Enrolling

HIV-1-infection

Drug: Stable Baseline Regimen

Drug: Bictegravir

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing re...

Active, not recruiting

HIV-1-infection

Drug: Optimized Background Regimen (OBR)

Drug: Oral Lenacapavir Placebo

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms